Molecular Biomedicine

SCIE

国际简称：Molecular Biomedicine 参考译名：分子生物医学

主要研究方向：Biochemistry, Genetics and Molecular Biology-Molecular Medicine 非预警期刊审稿周期：10 Weeks

《分子生物医学》(Molecular Biomedicine)是一本由Springer出版的以Biochemistry, Genetics and Molecular Biology-Molecular Medicine为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

2区中科院分区
Q1 JCR分区
128 年发文量
13 IF影响因子
未开放 是否OA
English 出版语言

Molecular Biomedicine, launched in 2020, is a peer-reviewed, open access journal published annually. It is a collaborative venture between the globally renowned scientific publishing company Springer Nature and the Sichuan Association for the Promotion of International Medical Exchange. This journal is dedicated to publishing high-quality research in the field of biomedicine from a molecular perspective, encompassing both fundamental and clinical studies.

Focusing on the mechanisms of human disease, as well as advancements in prevention, diagnosis, and treatment, Molecular Biomedicine aims to become a leading international academic journal with a significant impact in the biomedicine sector. The journal's commitment to open access ensures that its content is widely accessible, fostering global exchange of scientific knowledge and accelerating the dissemination of breakthroughs in molecular medicine.By embracing innovative research methodologies and interdisciplinary approaches, Molecular Biomedicine is positioned to contribute to the advancement of medical science, offering insights that could potentially lead to improved healthcare outcomes. The journal's editorial board, composed of experts from around the world, ensures that the published work meets the highest standards of scientific rigor and integrity, solidifying its reputation as a trusted source of information in the scientific community.

[ 查看全部 ]

投稿咨询加急咨询

Molecular Biomedicine期刊信息

ISSN：2662-8651
出版语言：English
是否OA：未开放
E-ISSN：2662-8651
出版地区：Switzerland
是否预警：否
出版商：Springer
Gold OA文章占比：100.00%
研究类文章占比：55.47%

Molecular Biomedicine CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

11.7

2.99

2.061

学科类别	分区	排名	百分位
大类：Biochemistry, Genetics and Molecular Biology 小类：Molecular Medicine	Q1	22 / 179	87%
大类：Biochemistry, Genetics and Molecular Biology 小类：Molecular Biology	Q1	53 / 414	87%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Molecular Biomedicine中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学 CELL BIOLOGY 细胞生物学 MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验	2区 2区 2区

Molecular Biomedicine JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：BIOCHEMISTRY & MOLECULAR BIOLOGY	ESCI	Q1	22 / 328	93.4
学科：CELL BIOLOGY	ESCI	Q1	25 / 207	88.2
学科：MEDICINE, RESEARCH & EXPERIMENTAL	ESCI	Q1	15 / 191	92.4
学科：BIOCHEMISTRY & MOLECULAR BIOLOGY	ESCI	Q1	49 / 328	85.21
学科：CELL BIOLOGY	ESCI	Q1	39 / 207	81.4
学科：MEDICINE, RESEARCH & EXPERIMENTAL	ESCI	Q1	39 / 191	79.84

Molecular Biomedicine历年数据统计

影响因子

中科院分区

Molecular Biomedicine中国学者发文选摘

1、PFKP is required for chemoresistant phenotype of breast cancer through modulating the formation of CD133+ cancer stem like cell
Author: Fang, Kai; Ma, Yue; Li, Lihua; Yue, Yan; Ruan, Hang; Xiong, Sidong

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00454-z
2、DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospect
Author: Zhao, Rui; Wang, Changli; Li, Jiamei; Liao, Yan; Huang, Chenwei; Hu, Ting; Zhang, Haoling; Zhang, Wangzheqi

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00456-x
3、In vivo CAR-cell therapy: current challenges and emerging therapeutic advance
Author: Yang, Yi-Min; Bao, Bo; Cao, Yu-Hao; Yao, Jin; Ding, Yu-Fan; Hu, Yi-Yang; Fan, Fan; Zhao, Jun-Long

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00447-y
4、The tumor suppressor NDRG2 promotes ACC1 proteasomal degradation and inhibits de novo lipogenesis in hepatocellular carcinom
Author: Shi, Qianqian; Bai, Yu; Wang, Jiayuan; Ru, Mengyao; Zhang, Kun; Guo, Yan; Bai, Zhantao; Shen, Lan

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00451-2
5、Amelioration of acute liver failure by a cinnamic acid derivative through inhibition of the ROS-NETosis axi
Author: Yin, Jie; Ding, Longjie; Zhao, Ziming; Chen, Xia; Huang, Jianzheng; Xiao, Yang; Gu, Lianghu; Zhang, Xiaotian; Tong, Qingyi; Zhang, Yonghui

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00448-x
6、Targeting ANXA1/TRKA axis enhances immunotherapy sensitivity in neural invasion-positive gastric cance
Author: Jiang, Tianlu; Zhou, Peng; Shen, Yikai; Lin, Jie; Li, Ying; Shen, Xusheng; Fang, Lang; Xu, Penghui; Xu, Zekuan; Wang, Linjun; Xia, Yiwen

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00444-1
7、Parkinson's disease: pathogenesis and therapeutic strategie
Author: Zhang, Shanshan; Wang, Tingyu; Peng, Ye; Wang, Qianchen; Zhang, Zhao; Chu, Shifeng; Huang, Hefei; Chen, Naihong

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00445-0
8、Targeting the RNA-binding motif protein 15 suppresses prostate cancer progression and hormone therapy resistance by promoting androgen receptor degradatio
Author: Hu, Bintao; Li, Le; Jin, Zhenghui; Li, Qinyu; Wu, Yue; Chen, Jie; Liu, Jihong; Han, Chenglin; Wang, Tao

Journal: MOLECULAR BIOMEDICINE. 2026; Vol. 7, Issue 1, pp. -. DOI: 10.1186/s43556-026-00428-1